Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00878254
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
- Conditions
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT00877006
- Locations
- 🇺🇸
Teva Investigational Site 52, Fountain Valley, California, United States
🇺🇸Teva Investigational Site 72, Augusta, Georgia, United States
🇺🇸Teva Investigational Site 48, Chicago, Illinois, United States
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00866749
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00853008
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Clínica Teknon, Barcelona, Spain
🇪🇸Hospital de Fuenlabrada, Madrid, Spain
Treatment of Aggressive Localized Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 334
- Registration Number
- NCT00841945
- Locations
- 🇫🇷
Regional university hospital, Rennes, France
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00825149
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2018-09-25
- Target Recruit Count
- 27
- Registration Number
- NCT00809341
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Polish Lymphoma Research Group
- Target Recruit Count
- 250
- Registration Number
- NCT00801281
- Locations
- 🇵🇱
Silesian Medical University, Chair and Clinic of Haematology and Bone Marrow Transplantation, Katowice, Poland
🇵🇱Central Clinical Hospital, Ministry of Internal Matters and Administration; Clinic of Oncology, Haematology and Internal Diseases, Warszawa, Poland
🇵🇱Oncology Centre of Lublin Region, Lublin, Poland
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00787527
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 13
- Registration Number
- NCT00786669
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.